OverviewSuggest Edit
Orthofix is a medical device company focused on musculoskeletal products and therapies. It operates Orthofix Spine and Orthofix Extremities business units. The company develops, manufactures, and distributes reconstruction and regenerative spine and extremity products that empower surgeons to meet the needs of their patients.
| Type | Public | |
| Founded | 1980 | |
| HQ | Lewisville, TX, US | Map |
| Website | orthofix.com | |
| Employee Ratings | More | |
| Overall Culture | B | More |
Recent NewsAll News
- Orthofix Announces Board Chair Transition
- Orthofix Launches Nationwide Recycling Program to Improve Sustainability
- Orthofix Announces US and European Full Market Launch of FITBONE Limb-Lengthening System
- Orthofix Schedules Fourth Quarter and Full Year Earnings Release and Conference Call for February 26, 2021
Key People/Management at Orthofix
Jon Serbousek
Director, President, and Chief Executive Officer
Jill Mason
Chief Ethics and Compliance Officer
Kimberley Elting
Chief Legal and Development Officer
Doug Rice
Chief Financial Officer
Ehab Esmail
Senior Vice President of Quality, Regulatory and Clinical Affairs
Roberto Donadello
Senior Vice President, Global Operations
Orthofix Office Locations
Orthofix has offices in Lewisville, Sunnyvale, Sao Paulo, Arcueil and in 5 other locations
Lewisville, TX, US (HQ)
3451 Plano Pkwy
Sunnyvale, CA, US
501 Mercury Dr
Sao Paulo, BR
Alameda Santos, 1978 - conj 162, 16°andar - Jardim Paulista
Arcueil, FR
28 Villa Baudran 24
Paris, FR
259 Rue Saint-Honoré
Ottobrunn, DE
5 Siemensstraße
Orthofix Financials and Metrics
Orthofix Revenue
Orthofix's revenue was reported to be $406.56 m in FY, 2020
| USD | |
|---|---|
Revenue (Q1, 2021) | 105.6m |
Gross profit (Q1, 2021) | 79.7m |
Gross profit margin (Q1, 2021), % | 75.5% |
Net income (Q1, 2021) | (5.8m) |
EBIT (Q1, 2021) | (2.9m) |
Market capitalization (16-Jul-2021) | 739.3m |
Closing stock price (16-Jul-2021) | 37.8 |
Cash (31-Mar-2021) | 94.6m |
EV | 665.0m |
Orthofix's current market capitalization is $739.3 m.
Annual
Quarterly
| USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 108.7m | 111.5m | 111.7m | 109.1m | 115.9m | 113.5m | 104.8m | 73.1m | 111.0m | 105.6m |
Cost of goods sold | 24.1m | 22.8m | 24.0m | 23.7m | 25.8m | 24.9m | 23.4m | 23.2m | 26.2m | 25.9m |
Gross profit | 84.6m | 88.7m | 87.7m | 85.4m | 90.0m | 88.6m | 81.4m | 50.0m | 84.7m | 79.7m |
Gross profit Margin, % | 78% | 80% | 78% | 78% | 78% | 78% | 78% | 68% | 76% | 75% |
Annual
Quarterly
| USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
Cash | 77.1m | 45.7m | 53.8m | 46.7m | 52.1m | 56.8m | 57.7m | 172.9m | 79.8m | 94.6m |
Accounts Receivable | 77.2m | 74.4m | 74.4m | 79.6m | 80.6m | 79.7m | 77.8m | 67.4m | 73.1m | 69.7m |
Prepaid Expenses | 31.2m | 35.6m | 34.5m | 16.4m | 21.0m | 19.6m | 21.2m | 20.7m | 18.5m | 14.4m |
Inventories | 77.7m | 81.7m | 79.9m | 79.1m | 79.1m | 81.0m | 82.7m | 82.0m | 82.9m | 84.2m |
Annual
Quarterly
| USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 5.2m | 6.2m | 4.9m | 897.0k | 350.0k | (40.1m) | 25.7m | 7.2m | 11.9m | (5.8m) |
Depreciation and Amortization | 4.4m | 8.9m | 13.7m | 5.7m | 11.9m | 18.2m | 6.3m | 13.3m | 22.3m | 7.4m |
Inventories | 1.7m | 5.3m | 6.9m | (2.5m) | (2.4m) | (5.0m) | (848.0k) | 468.0k | 246.0k | 16.0k |
Accounts Payable | (4.5m) | (3.8m) | (2.8m) | 1.9m | 1.6m | 447.0k | 28.0k | (4.8m) | (3.1m) | (1.5m) |
| USD | FY, 2017 |
|---|---|
Revenue/Employee | 505.6k |
Financial Leverage | 1.4 x |
Orthofix Revenue Breakdown
Orthofix revenue breakdown by business segment: 42.9% from Bone Growth Therapies, 20.6% from Spinal Implants, 14.2% from Biologics and 22.3% from Orthofix Extremities
Orthofix revenue breakdown by geographic segment: 78.7% from United States and 21.3% from Other
Orthofix Environment, Social & Governance (ESG) Ratings
Orthofix Online and Social Media Presence
Orthofix's Trends
Orthofix Company Culture
Overall Culture
B
72/100
CEO Rating
C-
63/100
Compensation
A
83/100
Diversity
B
72/100
Orthofix News and Updates
April 07, 2021
Orthofix Announces Board Chair Transition
Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and extremities focus, today announced that Ron Matricaria, Chairman of the Orthofix Board of Directors since 2014, has decided not to stand for re-election at the Company’s 2021 Annual Meeting in order to focus on ot…
March 10, 2021
Orthofix Launches Nationwide Recycling Program to Improve Sustainability
Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and extremities focus, today announced the launch of a nationwide recycling program to improve sustainability efforts. Orthofix is the first and only company in the U.S. to offer a free recycling program so patients c…
February 11, 2021
Orthofix Announces US and European Full Market Launch of FITBONE Limb-Lengthening System
Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and extremities focus, today announced the U.S. and European full market launch of the FITBONE® intramedullary lengthening system for limb lengthening and deformity correction of the femur and tibia bones
February 11, 2021
Orthofix Schedules Fourth Quarter and Full Year Earnings Release and Conference Call for February 26, 2021
Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and extremities focus, today announced that it plans to release financial results for the fourth quarter and full year 2020 before market open on Friday, February 26, 2021. Jon Serbousek, President and Chief Executive …
February 11, 2021
Orthofix to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Virtual Conference on February 19
Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and extremities focus, today announced that President and Chief Executive Officer Jon Serbousek and Chief Financial Officer Doug Rice will participate in a fireside chat during the BTIG MedTech, Digital Health, Life Sc…
Orthofix Blogs
May 05, 2021
Olympian and Orthofix Patient Laura Wilkinson Goes for the Gold Once Again
Your browser does not support the video tag. Orthofix is a proud sponsor of Olympian Laura Wilkinson for the Olympic Games, now scheduled for summer 2021 “In order to do things no one has ever done, you have to be willing to do things no one else is willing to do.” Laura Wilkinson made history…
October 07, 2020
Orthofix Launches O-GENESIS Graft Delivery System and New Hydrated, Ready-to-Use AlloQuent Structural Allograft Q-PACK
Orthofix Launches O-GENESIS Graft Delivery System and New Hydrated, Ready-to-Use AlloQuent Structural Allograft Q-PACK
Content Import
Wed, 10/07/2020 - 07:00
Orthofix Launches O-GENESIS Graft Delivery System and New Hydrated, Ready-to-Use AlloQuent Structural Allograft Q-PACK
…
October 06, 2020
Orthofix Announces Presentation of Clinical and Scientific Abstracts During the North American Spine Society Annual Meeting
Orthofix Announces Presentation of Clinical and Scientific Abstracts During the North American Spine Society Annual Meeting
Content Import
Tue, 10/06/2020 - 07:01
Orthofix Announces Presentation of Clinical and Scientific Abstracts During the North American Spine Society Annual Meeting
…
October 01, 2020
Orthofix FIREBIRD SI Fusion System Receives Additional FDA Clearance for Nanotechnology
Orthofix FIREBIRD SI Fusion System Receives Additional FDA Clearance for Nanotechnology
Content Import
Thu, 10/01/2020 - 07:01
Orthofix FIREBIRD SI Fusion System Receives Additional FDA Clearance for Nanotechnology
10/01/20
This release is a backfill from a Ne…
September 22, 2020
Orthofix and Neo Medical Announce Partnership to Develop and Market Single-Use Spinal Solutions Focused on Improving Patient Outcomes
Orthofix and Neo Medical Announce Partnership to Develop and Market Single-Use Spinal Solutions Focused on Improving Patient Outcomes
Content Import
Tue, 09/22/2020 - 07:00
Orthofix and Neo Medical Announce Partnership to Develop and Market Single-Use Spinal Solutions Focused on Improving …
Orthofix Frequently Asked Questions
When was Orthofix founded?
Orthofix was founded in 1980.
Who are Orthofix key executives?
Orthofix's key executives are Jon Serbousek, Jill Mason and Kimberley Elting.
How many employees does Orthofix have?
Orthofix has 1,055 employees.
What is Orthofix revenue?
Latest Orthofix annual revenue is $406.6 m.
What is Orthofix revenue per employee?
Latest Orthofix revenue per employee is $385.4 k.
Who are Orthofix competitors?
Competitors of Orthofix include Medtronic, Bioventus and Mammotome.
Where is Orthofix headquarters?
Orthofix headquarters is located at 3451 Plano Pkwy, Lewisville.
Where are Orthofix offices?
Orthofix has offices in Lewisville, Sunnyvale, Sao Paulo, Arcueil and in 5 other locations.
How many offices does Orthofix have?
Orthofix has 9 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies